Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.14% is 82% below its 5-year average of 0.76%, near the low end of its 5-year range (0.00%–1.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 77.80% below its 12-month average of 0.61%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.14%.
DEBT TO ASSETS RATIO
0.14%
DEBT TO ASSETS RATIO AVG TTM
0.61%
DEBT TO ASSETS RATIO AVG 3Y
0.68%
DEBT TO ASSETS RATIO AVG 5Y
0.76%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-77.80%
CURRENT VS 3Y AVG
-80.18%
CURRENT VS 5Y AVG
-82.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+50.71%
vs the sector median at left
Olema Pharmaceuticals, Inc.
Market Cap
$698.34M
Debt to Assets Ratio
0.14%
TTM Avg
0.61%
3Y Avg
0.68%
5Y Avg
0.76%
Market Cap
$696.06M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$693.59M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$685.70M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$713.24M
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$716.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$718.68M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$722.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $698.34M | 0.14% | 0.61% | 0.68% | 0.76% |
| Anteris Technologies Global Corp. (AVR)vs › | $696.06M | 0.01% | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $693.59M | 0.08% | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $689.37M | 0.41% | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $685.70M | 0.05% | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $713.24M | 0.40% | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $716.43M | 0.00% | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $718.68M | 0.06% | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $722.58M | 0.00% | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $673.84M | 0.08% | N/A | N/A | N/A |
Debt/Assets
0.1%
Debt/Equity
0.00
Current Ratio
8.86
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.14% |
| 2026-03-31 | 0.18% |
| 2025-12-31 | 0.22% |
| 2025-09-30 | 1.27% |
| 2025-06-30 | 1.24% |
| 2025-03-31 | 0.28% |
| 2024-12-31 | 0.32% |
| 2024-09-30 | 0.74% |
| 2024-06-30 | 0.77% |
| 2024-03-31 | 0.84% |
| 2023-12-31 | 0.87% |
| 2023-09-30 | 0.90% |
| 2023-06-30 | 1.13% |
| 2023-03-31 | 1.17% |
| 2022-12-31 | 1.19% |
| 2022-09-30 | 1.22% |
| 2022-06-30 | 1.23% |
| 2022-03-31 | 1.10% |
| 2021-12-31 | 1.11% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2019-12-31 | 0.00% |
